Vytorin: Science Vs. Hype

If one cholesterol-lowering drug is good, two must be better. That was the thinking behind Vytorin, a combination of Merck's Zocor and Schering-Plough's Zetia. Not so, it turns out. A study of 750 patients showed that while the combination did lower bad cholesterol, or LDL, it did little more to reduce the dangerous buildup of plaque than Zocor alone did — which costs far less than the combination drug Vytorin.

• 
• Click to Print

• Find this article at:
• https://content.time.com/time/specials/packages/article/0,28804,1860289_1859836_1859848,00.html